These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 10164503)
1. Hormone replacement therapy: a review of the risk versus benefit--Part II. Oates MB; McGhan WF; Smith MD Med Interface; 1997 Jan; 10(1):108-14. PubMed ID: 10164503 [TBL] [Abstract][Full Text] [Related]
2. A computer model to analyze the cost-effectiveness of hormone replacement therapy. Zethraeus N; Johannesson M; Jönsson B Int J Technol Assess Health Care; 1999; 15(2):352-65. PubMed ID: 10507194 [TBL] [Abstract][Full Text] [Related]
3. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat. Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of continuous combined hormone replacement therapy in long-term use: economic evaluation based on a 9-year study in Finland. Ylikangas S; Bäckström T; Heikkinen J Curr Med Res Opin; 2007 Jan; 23(1):57-64. PubMed ID: 17257466 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Mobley LR; Hoerger TJ; Wittenborn JS; Galuska DA; Rao JK Med Decis Making; 2006; 26(2):194-206. PubMed ID: 16525173 [TBL] [Abstract][Full Text] [Related]
6. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy. Genazzani AR; Gadducci A; Gambacciani M Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941 [TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Salpeter SR; Buckley NS; Liu H; Salpeter EE Am J Med; 2009 Jan; 122(1):42-52.e2. PubMed ID: 19114171 [TBL] [Abstract][Full Text] [Related]
8. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Skouby SO; Al-Azzawi F; Barlow D; Calaf-Alsina Erdogan Ertüngealp J; Gompel A; Graziottin A; Hudita D; Pines A; Rozenberg S; Samsioe G; Stevenson JC; Maturitas; 2005 May; 51(1):8-14. PubMed ID: 15883103 [TBL] [Abstract][Full Text] [Related]
9. Physician counseling on hormone replacement therapy and bone loss: do socioeconomic and racial characteristics of women influence counseling? Neuner JM; McCarthy EP; Davis RB; Phillips RS J Womens Health (Larchmt); 2003 Jun; 12(5):495-504. PubMed ID: 12869297 [TBL] [Abstract][Full Text] [Related]
10. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003. Burger H Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798 [TBL] [Abstract][Full Text] [Related]
11. Osteoporosis and cardiovascular disease: benefit-risk of hormone replacement therapy. Sammartino A; Cirillo D; Mandato VD; Di Carlo C; Nappi C J Endocrinol Invest; 2005; 28(10 Suppl):80-4. PubMed ID: 16550729 [TBL] [Abstract][Full Text] [Related]
13. Menopausal depression: comparison of hormone replacement therapy and hormone replacement therapy plus fluoxetine. Liu P; He FF; Bai WP; Yu Q; Shi W; Wu YY; He DJ; Xiao JH; Zheng Y; Liao QP Chin Med J (Engl); 2004 Feb; 117(2):189-94. PubMed ID: 14975200 [TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy in women with past history of endometriosis. Soliman NF; Hillard TC Climacteric; 2006 Oct; 9(5):325-35. PubMed ID: 17000581 [TBL] [Abstract][Full Text] [Related]
15. Comparative cardiovascular effects of different progestins in menopause. Rosano GM; Fini M Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197 [TBL] [Abstract][Full Text] [Related]